ACELYRIN INC (SLRN) Stock Price, Forecast & Analysis
NASDAQ:SLRN • US00445A1007
SLRN Key Statistics, Chart & Performance
The current stock price of SLRN is 2.27 USD. In the past month the price decreased by -2.99%. In the past year, price decreased by -45.04%.
SLRN Technical Analysis
SLRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLRN. No worries on liquidiy or solvency for SLRN as it has an excellent financial health rating, but there are worries on the profitability.
SLRN Financial Highlights
Over the last trailing twelve months SLRN reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.52% | ||
| ROE | -65.94% | ||
| Debt/Equity | 0 |
SLRN Forecast & Estimates
8 analysts have analysed SLRN and the average price target is 8.16 USD. This implies a price increase of 259.47% is expected in the next year compared to the current price of 2.27.
SLRN Ownership
SLRN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLRN
Company Profile
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 83 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Company Info
ACELYRIN INC
4149 Liberty Canyon Rd.
Agoura Hills CALIFORNIA US
Employees: 93
Phone: 18054564393
ACELYRIN INC / SLRN FAQ
What does ACELYRIN INC do?
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 83 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
What is the current price of SLRN stock?
The current stock price of SLRN is 2.27 USD. The price increased by 1.79% in the last trading session.
Does SLRN stock pay dividends?
SLRN does not pay a dividend.
How is the ChartMill rating for ACELYRIN INC?
SLRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ACELYRIN INC (SLRN) stock?
8 analysts have analysed SLRN and the average price target is 8.16 USD. This implies a price increase of 259.47% is expected in the next year compared to the current price of 2.27.
Can you provide the PE ratio for SLRN stock?
ACELYRIN INC (SLRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.99).
What is the employee count for SLRN stock?
ACELYRIN INC (SLRN) currently has 93 employees.